Optimistic Buy Rating for Schrodinger Amid Promising Drug Developments and Strategic Growth Potential

Analyst David Lebowitz of Citi maintained a Buy rating on Schrodinger (SDGR – Research Report), with a price target of $39.00.

David Lebowitz has given his Buy rating due to a combination of factors related to Schrodinger’s recent developments and future potential. The company has shared promising data for its internally developed drug, SGR-1505, which is a MALT1 inhibitor currently being tested in Phase 1 trials for recurring or relapsing B-cell malignancies. The data revealed an overall response rate of 22%, with notable responses in patients with Waldenstrom’s macroglobulinemia, indicating potential efficacy.
Although there is room for improvement in efficacy, the drug’s tolerability suggests that further dose escalations could enhance its effectiveness. Schrodinger’s management plans to explore the drug’s use in more aggressive tumor types and in combination with other therapies, which could unlock further potential. Despite the early stage of development, the expected share price return of 46.1% reflects optimism about the company’s strategic direction and the drug’s future prospects.

SDGR’s price has also changed slightly for the past six months – from $21.070 to $22.835, which is a 8.38% increase.